Velcade Shows Edge In Phase III Multiple Myeloma Trial; Fails In Colorectal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Millennium plans to submit its Phase III Velcade (bortezomib) confirmatory trial in multiple myeloma in the second half of 2004.
You may also be interested in...
Millennium Velcade Has 50%-60% Of Third-Line Multiple Myeloma Market
Millennium’s Velcade captured 50% to 60% of the third-line multiple myeloma market in the second quarter, the firm reported July 22.
Neuropathy Associated With Velcade Appears Reversible, Analysis Shows
Peripheral neuropathy associated with Millennium’s Velcade appears to be reversible in most cases, according to an analysis presented at the American Society of Hematology annual meeting Dec. 9.
Velcade "Impressive" Efficacy Offsets Concerns Over Response As Endpoint
"Impressive" and "better than expected" efficacy results with Millennium’s multiple myeloma agent Velcade were enough to outweigh FDA’s concerns about the use of response rate as a surrogate endpoint, NDA review documents indicate.